Clinical Research Directory

Inclusion Criteria: * (1) sinonasal inflammation for greater than 12 weeks which include at least 2 of the following symptoms: nasal obstruction/congestion, nasal discharge (anterior or posterior), facial pressure/pain, reduction of sense of smell. * (2) confirmation of the clinical symptoms by: (2a) CT scan evidence of paranasal sinus mucosal inflammation, and/or (2b) endoscopic exam evidence of purulence from the sinuses or ostiomeatal complex; and * (3) presence of nasal polyps seen on endoscopic exam or sinus CT scan. Exclusion Criteria: * 1\. Children under the age of 18 will be excluded due to: 1. possible confounding diagnosis of cystic fibrosis and other non-Type 2 inflammatory etiologies that commonly presents with nasal polyps in the pediatric population. 2. lack of complete pneumatization of the majority of paranasal sinuses * 2\. pregnant or lactating females, * 3\. prisoners, * 4\. mentally disabled * 5\. persons unable to give informed consent will be contemplated for inclusion. * 6\. disease secondary to a clearly defined anatomic process, such as facial trauma, and obstruction due to sinonasal neoplasm. * 7\. exposure to oral or systemic IV glucocorticoids within 2 weeks of surgery * 8\. exposure to immunomodulatory biologics will be excluded. These include, but are not limited to systemic treatment with biologics omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, or rituximab.